DURHAM, N.C., July 11, 2023 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading multi-specialty clinical sites business, and Privia Health (Nasdaq: PRVA), a physician enablement company serving more than 3,700 providers and 4.4 million patients, today announced a partnership to open embedded clinical research sites within Privia’s practice network.
The partnership is intended to establish integrated research sites within existing Privia Care Center locations that do not currently conduct clinical trials. Velocity will staff and operate the joint research sites, bringing management experience in clinical trial operations and patient recruitment.
The first of these sites is in West Texas Health, a clinic in Abilene, Texas, led by Thomas Headstream, MD. The site, located in a medical mall with specialty clinics, will bring research opportunities to Abilene’s diverse community.
Keith Fernandez, MD, Privia Health Chief Clinical Officer, said, “The Privia Clinical Research program supports our Company’s mission to provide great care to patients and lighten the administrative burden for physicians and their practices. Velocity has an excellent reputation, and we look forward to gaining the benefits of this partnership.”
The partnership gives Velocity access to a large, integrated network of multi-specialty providers, which will expand its therapeutic base in specialty care and increase the number of physicians becoming Principal Investigators at a time when there is a chronic long-term decline in investigator numbers.
Paul Evans, PhD, Velocity President and Chief Executive Officer, added: “Velocity has the people and Privia has the coverage. By bringing professional management of clinical trials to specialty care, we are opening up research opportunities for more patients. Through an embedded model, Privia benefits from increased activity at their clinics and Velocity has the opportunity to move into new therapeutic areas. We expect to see more partnerships of this kind, as the clinical trials landscape matures and achieves the scale to work with established organizations, like Privia.”
Velocity’s acquisition of Meridian Clinical Research in December 2022 accelerated its move into specialty care through an embedded site model strategy. As part of its own growth, Meridian pioneered a site model that focused on establishing dedicated research facilities in clinical practices. Velocity will continue to expand on this model and leverage it through strategic partnerships.
About Velocity Clinical Research
Velocity is the leading integrated site organization for clinical trials. With 80 sites and more than 220 investigators, Velocity partners with pharmaceutical and biotechnology companies to research new drugs, medical devices, diagnostics, and combination products that could improve human health and wellbeing. Velocity offers unified research site solutions to efficiently provide the right patients, investigators, and research staff for clinical trials across the U.S. and Europe. The company also operates a technology hub in India, where it is unlocking a new era in clinical research by developing innovative systems to leverage expansive site, patient, and historical performance data. To learn more about how Velocity delivers high-quality data, exemplary patient care, and unprecedented efficiency for clinical trials at any scale, visit VelocityClinical.com.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. The Privia Platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Last Trade: | US$21.56 |
Daily Change: | 0.48 2.28 |
Daily Volume: | 585,735 |
Market Cap: | US$2.580B |
November 07, 2024 October 29, 2024 August 08, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB